🏛️ Verified NIH Record • Updated 2026-08-18

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (NCT05774951)

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.

Who can join: Review the eligibility criteria below.

Location: Research Site — Birmingham, Alabama

Age range: 18 Years to 130 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (709 Sites)

Showing the first 25 of 709 sites.

  • Research Site — Birmingham, Alabama
  • Research Site — Dothan, Alabama
  • Research Site — Anchorage, Alaska
  • Research Site — Chandler, Arizona
  • Research Site — Hot Springs, Arkansas
  • Research Site — Anaheim, California
  • Research Site — Beverly Hills, California
  • Research Site — Concord, California
  • Research Site — Corona, California
  • Research Site — Fountain Valley, California
  • Research Site — Greenbrae, California
  • Research Site — Los Alamitos, California
  • Research Site — Palo Alto, California
  • Research Site — San Diego, California
  • Research Site — San Diego, California
  • Research Site — Whittier, California
  • Research Site — Aurora, Colorado
  • Research Site — Hartford, Connecticut
  • Research Site — Fort Myers, Florida
  • Research Site — Gainesville, Florida
  • Research Site — Miami Beach, Florida
  • Research Site — Orlando, Florida
  • Research Site — Plantation, Florida
  • Research Site — Port Saint Lucie, Florida
  • Research Site — Saint Augustine, Florida

📞 Contact the Study Coordinator

Phone: (877) 240-9479

Email: information.center@astrazeneca.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Breast Cancer, Early Breast Cancer

Explore by condition: All Breast Cancer, Early Breast Cancer clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗